ERBB2 and neoplasm: The phase II study (KAMELEON, NCT02999672) provides support for the potential use of T‐DM1 monotherapy as a treatment option regardless of tumor type for patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.131